Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4386 - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Ana De Jesus-Acosta

Citation

Annals of Oncology (2019) 30 (suppl_5): v194-v197. 10.1093/annonc/mdz245

Authors

A. De Jesus-Acosta1, G. Crespo Herrero2, M.L. Gómez-Dorronsoro3, V. Alonso4, M.C. Riesco Martinez5, A. Custodio6, C. Lopez7, M. Benavent8, A. Carmona Bayonas9, P. Jimenez-Fonseca10, M. Llanos11, B. López De San Vicente12, V. Arrazubi Arrula13, R. Grandez14, I. González-Borja15, S. Goñi15, I. Arozarena16, M. Baretti17, A. Viudez18

Author affiliations

  • 1 Medical Oncology, Johns Hopkins Hospital, 21231 - Baltimore/US
  • 2 Medical Oncology, Hospital Universitario de Burgos (HUBU), 09006 - Burgos/ES
  • 3 Pathology, Complejo Hospitalario de Navarra - Royal Navarre Hospital, 31008 - Pamplona/ES
  • 4 Medical Oncology, Miguel Servet University Hospital, Zaragoza/ES
  • 5 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 6 Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 7 Medical Oncology, Marques de Valdecilla University Hospital, Santander/ES
  • 8 Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 9 Hematology And Medical Oncology, Hospital Universitario Morales Meseguer, 30008 - Murcia/ES
  • 10 Medical Oncology, Hospital Universitario Central de Oviedo, Oviedo/ES
  • 11 Servicio De Oncología Médica, Hospital Universitario de Canarias, Santa Cruz de Tenerife/ES
  • 12 Medical Oncology, Hospital de Basurto, 48013 - Bilbao/ES
  • 13 Medical Oncology, Complejo Hospitalario de Navarra, 31008 - Pamplona/ES
  • 14 Medical Oncology, Hospital Tudela, Tudela/ES
  • 15 Oncobionatras, Navarrabiomed, 31008 - Pamplona/ES
  • 16 Tumor Cell Signaling, Navarrabiomed, 31008 - Pamplona/ES
  • 17 Oncology, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 18 Medical Oncology, Complejo Hospitalario de Navarra - Royal Navarre Hospital, 31008 - Pamplona/ES
More

Resources

Abstract 4386

Background

Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET. The present multicenter project is retrospectively analyzing the predictive/prognosis role of MGMT, NDRG-1 and PHLDA-3 in patients with advanced PanNET treated CAPTEM or everolimus.

Methods

IHC nuclear staining for MGMT and PHLDA-3 is being scored as 0, 1-5%, 6-50% and ≥ 51%. For NDRG-1, we are using a cytoplasmic score from 0 to 3 based on staining intensity and distribution pattern (patched or diffuse).

Results

Until now, clinical and samples data from 96 patients (110 samples) has been collected ad are currently being analyzed. Based on our previous results, we will develop an imunohistochemistry prognostic score (IPS, score from 0 to 4) and try to correlate it with clinical variables collected in our database.

Conclusions

As we described previously in operated PanNET, we will try to describe the potential role of IPS as predictive/ prognostic factor in advanced PanNET. More mature results of this work will be presented during 2019 ESMO Congress.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Navarrabiomed Biomedical Research Center, Pamplona, Navarra, Spain.

Funding

GETNE.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings